Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
09:31am, Tuesday, 05'th Nov 2024
UniQure (QURE) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $1.88 per share a year ago.
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
07:05am, Tuesday, 05'th Nov 2024
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:06am, Tuesday, 29'th Oct 2024
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
07:05am, Tuesday, 15'th Oct 2024
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
07:05am, Monday, 23'rd Sep 2024
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
07:05am, Thursday, 15'th Aug 2024
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
03:03am, Tuesday, 06'th Aug 2024
uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
09:25am, Thursday, 01'st Aug 2024
UniQure (QURE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.44 per share a year ago.
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
07:05am, Thursday, 01'st Aug 2024
~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegener
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
10:55am, Friday, 26'th Jul 2024
The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
07:05am, Tuesday, 23'rd Jul 2024
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~
What Led To A 150% Rise In UniQure Stock In A Week?
08:00am, Friday, 12'th Jul 2024
uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
10:55am, Wednesday, 10'th Jul 2024
The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
uniQure (QURE) Soars on New Huntington's Disease Study Data
10:06am, Wednesday, 10'th Jul 2024
uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
06:50am, Wednesday, 10'th Jul 2024
uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength do
